Podaci iz realnog života o efikasnosti i bezbednosti ombitasvir/ /paritaprevir/ritonavir + dasabuvir + ribavirin režima kod bolesnika sa genotip 1 hepatitis C virusnom infekcijom u Srbiji

  • Jasmina Simonović Babić University of Belgrade, Faculty of Medicine, Belgrade, Serbia
  • Ksenija Bojović University of Belgrade, Faculty of Medicine, Belgrade, Serbia
  • Milotka Fabri University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
  • Tatjana Cvejić Clinical Centre of Serbia, Clinic for Gastroenterology, Belgrade, Serbia
  • Petar Svorcan Clinical Hospital Centre “Zvezdara”, Department of Hepatology and Gastroenterology, Belgrade, Serbia
  • Darko Nožić Military Medical Academy, Clinic for Infectious Diseases, Belgrade, Serbia
  • Maja Jovanović University of Niš, Faculty of Medicine, Niš, Serbia
  • Ranko Škrbić University of Banja Luka, Faculty of Medicine, Department of Pharmacology, Toxicology and Clinical Pharmacology, Banja Luka, Republic of Srpska, Bosnia and Herzegovina
  • Miloš P. Stojiljković University of Banja Luka, Faculty of Medicine, Department of Pharmacology, Toxicology and Clinical Pharmacology, Banja Luka, Republic of Srpska, Bosnia and Herzegovina
  • Željko Mijailović Clinical Centre of Kragujevac, Clinic for Infectious Diseases, Kragujevac, Serbia
DOI: https://doi.org/10.2298/VSP170727186S
Ključne reči: antivirotici;, lečenje, kombinovano;, hepatitis c, hronični;, ritonavir;, ombitasvir;, paritaprevir;, dasabuvir;, ribavirin.

Sažetak


Uvod/Cilj. Era direktno delujućeg antivirusnog (DAA) režima lečenja bolesnika sa hroničnom hepatitis C virusnom (HCV) infekcijom započela je 2011. godine. Cilj rada bio je ispitivanje efikasnosti i bezbednosti DAA režima ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) + dasabuvir (DSV) + ribavirin (RBV), kod bolesnika sa genotip 1 HCV infekcijom u Srbiji. Metode. U multicentričnu studiju je bilo uključeno sedam centara u Srbiji. Prikupljeni su podaci iz realnog života. U rani pristupni program OBV/PTV/r + DSV + RBV bio je uključen 21 bolesnik od kojih jedan nije prethodno lečen, dok je ostalih 20 prethodno lečeno pegilovanim interferonom i RBV. Svi bolesnici su dobijali odgovarajuće doze lekova. Bolesnici sa HCV genotipom 1b nisu dobijali RBV u skladu sa terapijskim protokolom. Za većinu bolesnika trajanje terapije je iznosilo 12 nedelja. Za četvoro bolesnika sa cirozom i HCV genotipom 1a trajanje terapije je iznosilo 24 nedelje. Viremija je određivana četiri puta: pre početka terapije, 4 nedelje posle početka terapije (rapidni virusološko odgovor – RVR), 12 ili 24 nedelje nakon početka terapije (kraj terapije – ETR) i 12 nedelja nakon završetka terapije (stabilan virusološki odgovor – SVR). Postignut SVR kao potvrda odsustva virusne RNK u serumu, smatran je završnicom uspešnog lečenja. Rezultati. Kompletan RVR, ETR i SVR postignut je kod 64,71%, 85,71%, i 95,24% bolesnika sukcesivno. Samo 3 bolesnika imali su blage neželjene efekte koji nisu zahtevali korekciju doze lekova. Zaključak. Lečenje bolesnika sa hroničnom HCV infekcijom sa OBV/PTV/r + DSV + RBV pokazalo je odličnu antivirusnu aktivnost i podnošljivost.

Reference

Franciscus A. A brief history of hepatitis C. HCSP version 4.4. 2017 Feb [cited 2017 May 19]. Available from: http://www.hcvadvocate.org/hepatitis/factsheets_pdf/Brief_History_HCV.pdf.

Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61: 77–87.

Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118(12): 3030–44.

World Health Organization (WHO). Hepatitis C – Fact sheet 2014 [cited 2017 Jan 15]. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/.

Petrović J, Salkić NN, Ahmetagić S, Stojić V, Mott-Divković S. Prevalence of chronic hepatitis B and hepatitis C among first time blood donors in Northeast Bosnia and Herzegovina: en estimate of prevalence in general population. Hepat Mon 2011; 11(8): 629–33.

Mitrović N, Delić D, Marković-Denić L, Jovičić M, Popović N, Bojović K, et al. Seroprevalence and risk factors for hepatitis C virus infection among blood donors in Serbia: A multicentre study. Dig Liver Dis 2015; 47(7): 572–6.

Mitrović N. Epidemiological characteristics of hepatitis C viral infection in Serbia [dissertation]. Belgrade: Medical Faculty, University of Belgrade; 2015. (Serbian)

Lucejko M, Parfieniuk-Kowerda A, Flisiak R. Om-bitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection. Expert Opin Phar-macother 2016; 17(8): 1153–64.

Delić D, Mitrović N, Popović N, Urošević A, Pešiċ I, Simonoviċ J. Antiviral/immunomodulatory combination therapy: pegylated interferon alpha 2a and ribavirin in patients with chronic hep-atitis C virus infection. Srp Arh Celok Lek 2012; 140(9–10): 612–8. (Serbian)

Simonović Babić J, Bojović K, Fabri M, Kostić V, Jovanović M, Mijai-lović Ž, et al. Boceprevir in genotype 1 chronic hepatitis C: First experiences in Serbia. Srp Arh Celok Lek 2015; 143(1–2): 35–41.

Flisiak R, Janczewska E, Wawrzynowicz-Syczewska M, Wiercinska-Drapalo A, Zarebska-Michaluk D, Fleischer-Stepniewska K, et al. Efficacy and safety of Parytaprewir/r/Ombitaswir and Dazabuwir with or without Ribavirin in real life therapy of Polish patients with chronic hepatitis C – an interim analysis of AMBER study data. Clin Exp Hepatol 2015; 1(2): 84.

Flisiak R, Janczewska E, Mawrzynowicz-Syczewska M, Jaroszewicz J, Zarebska-Michaluk D, Nazzal K, et al. Real-world effective-ness and safety of ombitasvir/paritaprevir/ritonavir + da-sabuvir + ribavirin in hepatitis C: AMBER study. Aliment Pharmacol Ther 2016; 44: 946–56.

Feld J, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. J Hepatol 2016; 64: 301–7.

Pogorzelska J, Flisiak R. Real-world experience with om-bitasvir/paritaprevir boosted with ritonavir and possibly com-bined with dasabuvir and ribavirin in HCV infection. Clin Exp Hepatol 2016; 2(2): 34–7.

Lawitz E, Makara M, Akarca US, Thuluvath PJ, Preotescu LL, Varunok P, et al. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Pa-tients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis. Gastroenterology 2015; 149(4): 971–80.e1.

Van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological re-sponse and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308(24): 2584–93.

Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364(13): 1195–206.

Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Red-dy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364(25): 2405–16.

Bichoupan K, Tandon N, Martel-Laferriere V, Patel NM, Sachs D, Ng M, et al. Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection. World J Hepatol 2017; 9(11): 551–61.

Alswat KA, Babatin MA, Abdelrahman AA, Al-Hamoudi WK, Alghamdi AS, Abdo A, et al. Treatment of chronic hepatitis C genotype 4-infected patients with ombitasvir /paritaprevir /ritonavir plus ribavirin: Real life data from Saudi Arabia. Hepatology 2016; 64(1 Suppl): 974A–5A.

Rodriguez-Osorio I, Cid P, Morano L, Castro A, Suarez M, Delgado M, et al. Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients. J Clin Virol 2017; 88: 58–61.

McCombs J, McGinnis J, Fox S, Tonnu-Mihara J. Analysis of the real world effectiveness of direct acting antivirals treatments of hepatitis C in large population. J Hepatol 2016; 64(Suppl 2): S217.

Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infec-tion. Hepatology 2002; 35(5): 1002–9.

Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Comparative effectiveness of ledipasvir/sofosbuvir ± ribavi-rin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± rib-avirin in 6961 genotype 1 patients treated in routine medical practice. Aliment Pharmacol Ther 2016; 44(4): 400–10.

Objavljeno
2021/02/12
Broj časopisa
Vol. 76 Br. 5 (2019): Vojnosanit pregl
Rubrika
Kratko saopštenje